Abstract
Follicular lymphoma is the second most common type of non-Hodgkin's lymphoma. The outcome of patients with FL is generally favourable with exception of approximately 15-20% of patients with early progression within 24 months from the start of therapy.
Standard first-line therapy consist of immunochemotherapy followed by rituximab maintenance for 2 years. Obinutuzumab in combination with chemotherapy achieved better results in the first line treatment.
Therapy of relapsed disease is variable. Current best treatment strategy of rituximab refractory patients is combination of bendamustine and obinutuzumab with maintenance treatment with obinutuzumab for 2 years.
Thanks to many interesting new drugs (lenalidomid, ibrutinib, copanlisib etc.) prognosis of patients with FL has been improved over past 10 years and median of survival is now about 18-20 years. FL belongs to the one of the most favourable lymphoma.